BACKGROUND: Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to be demonstrated. We tested the hypothesis that a UCB-derived cell product consisting of stem cells expanded for 21 days in the presence of nicotinamide and a noncultured T cell fraction (NiCord) can accelerate hematopoietic recovery and provide long-term engraftment. METHODS: In a phase I trial, 11 adults with hematologic malignancies received myeloablative bone marrow conditioning followed by transplantation with NiCord and a second unmanipulated UCB unit. Safety, hematopoietic recovery, and donor engraftment were assessed and compared with historical controls. RESULTS: No adverse events were attributable to the infusion of NiCord. Complete or partial neutrophil and T cell engraftment derived from NiCord was observed in 8 patients, and NiCord engraftment remained stable in all patients, with a median follow-up of 21 months. Two patients achieved long-term engraftment with the unmanipulated unit. Patients transplanted with NiCord achieved earlier median neutrophil recovery (13 vs. 25 days, P < 0.001) compared with that seen in historical controls. The 1-year overall and progression-free survival rates were 82% and 73%, respectively. CONCLUSION: UCB-derived hematopoietic stem and progenitor cells expanded in the presence of nicotinamide and transplanted with a T cell-containing fraction contain both short-term and long-term repopulating cells. The results justify further study of NiCord transplantation as a single UCB graft. If long-term safety is confirmed, NiCord has the potential to broaden accessibility and reduce the toxicity of UCB transplantation. TRIAL REGISTRATION: Clinicaltrials.gov NCT01221857. FUNDING: Gamida Cell Ltd.
BACKGROUND: Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to be demonstrated. We tested the hypothesis that a UCB-derived cell product consisting of stem cells expanded for 21 days in the presence of nicotinamide and a noncultured T cell fraction (NiCord) can accelerate hematopoietic recovery and provide long-term engraftment. METHODS: In a phase I trial, 11 adults with hematologic malignancies received myeloablative bone marrow conditioning followed by transplantation with NiCord and a second unmanipulated UCB unit. Safety, hematopoietic recovery, and donor engraftment were assessed and compared with historical controls. RESULTS: No adverse events were attributable to the infusion of NiCord. Complete or partial neutrophil and T cell engraftment derived from NiCord was observed in 8 patients, and NiCord engraftment remained stable in all patients, with a median follow-up of 21 months. Two patients achieved long-term engraftment with the unmanipulated unit. Patients transplanted with NiCord achieved earlier median neutrophil recovery (13 vs. 25 days, P < 0.001) compared with that seen in historical controls. The 1-year overall and progression-free survival rates were 82% and 73%, respectively. CONCLUSION: UCB-derived hematopoietic stem and progenitor cells expanded in the presence of nicotinamide and transplanted with a T cell-containing fraction contain both short-term and long-term repopulating cells. The results justify further study of NiCord transplantation as a single UCB graft. If long-term safety is confirmed, NiCord has the potential to broaden accessibility and reduce the toxicity of UCB transplantation. TRIAL REGISTRATION: Clinicaltrials.gov NCT01221857. FUNDING: Gamida Cell Ltd.
Authors: Mary Eapen; John P Klein; Guillermo F Sanz; Stephen Spellman; Annalisa Ruggeri; Claudio Anasetti; Maria Brown; Richard E Champlin; Joan Garcia-Lopez; Gareth Hattersely; Gesine Koegler; Mary J Laughlin; Gerard Michel; Samir K Nabhan; Franklin O Smith; Mary M Horowitz; Eliane Gluckman; Vanderson Rocha Journal: Lancet Oncol Date: 2011-10-06 Impact factor: 41.316
Authors: M J Laughlin; J Barker; B Bambach; O N Koc; D A Rizzieri; J E Wagner; S L Gerson; H M Lazarus; M Cairo; C E Stevens; P Rubinstein; J Kurtzberg Journal: N Engl J Med Date: 2001-06-14 Impact factor: 91.245
Authors: Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman Journal: N Engl J Med Date: 2004-11-25 Impact factor: 91.245
Authors: C L Mackall; T A Fleisher; M R Brown; M P Andrich; C C Chen; I M Feuerstein; M E Horowitz; I T Magrath; A T Shad; S M Steinberg Journal: N Engl J Med Date: 1995-01-19 Impact factor: 91.245
Authors: Colleen Delaney; Shelly Heimfeld; Carolyn Brashem-Stein; Howard Voorhies; Ronald L Manger; Irwin D Bernstein Journal: Nat Med Date: 2010-01-17 Impact factor: 53.440
Authors: Mary Eapen; Elizabeth Raetz; Mei-Jie Zhang; Catherine Muehlenbein; Meenakshi Devidas; Thomas Abshire; Amy Billett; Alan Homans; Bruce Camitta; William L Carroll; Stella M Davies Journal: Blood Date: 2006-02-21 Impact factor: 22.113
Authors: Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Philip B McGlave; Jeffrey S Miller; Catherine M Verfaillie; John E Wagner Journal: Blood Date: 2004-10-05 Impact factor: 22.113
Authors: Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner Journal: Blood Date: 2007-06-14 Impact factor: 22.113
Authors: Jonathan A Gutman; Cameron J Turtle; Thomas J Manley; Shelly Heimfeld; Irwin D Bernstein; Stanley R Riddell; Colleen Delaney Journal: Blood Date: 2009-10-12 Impact factor: 22.113
Authors: Maia M Alexaline; Marina Trouillas; Muriel Nivet; Emilie Bourreau; Thomas Leclerc; Patrick Duhamel; Michele T Martin; Christelle Doucet; Nicolas O Fortunel; Jean-Jacques Lataillade Journal: Stem Cells Transl Med Date: 2015-04-06 Impact factor: 6.940
Authors: Ahmad Abu-Khader; Roya Pasha; Gwendoline C D Ward; Gavin Boisjoli; Nicolas Pineault Journal: Cytotechnology Date: 2016-10-18 Impact factor: 2.058